Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026

Akeso announced that nearly 30 clinical studies involving its first-in-class bispecific antibodies will be presented at the 2026 ESMO Congress. The breadth of presentations highlights continued clinical-development progress for the company’s oncology pipeline, though no efficacy data or regulatory milestones were disclosed in the announcement.